Language: BG BG
← Back to results
Recruiting Phase 4 2025-522381-68-00

Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial

Phase 4 – monitoring after market approval
Conditions: Severe refractory cancer pain

Sponsor: Vrije Universiteit Brussel

trial.available_in: БГ
Overview
Trial status: Authorised Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental, and social dimension., The survival rate in both groups, CMM and IDD, will be determined by recording the time from treatment initiation until death., Pain intensity will be measured with the VAS (ranging from 0 (no pain) to 100 (maximal pain)) in electronic format., Perceived stress will be assessed by using the 10-item Perceived Stress Scale (PSS; Cohen, Kamarch, & Mermelstein, 1983)., Patient anxiety will be provided through the State Trait Anxiety Inventory (STAI)., Using the Injustice Experience Questionnaire (IEQ), perceived injustice related to current health status will be assessed., The General Self-Efficacy (GSE) Scale is a 10-item self-report questionnaire used to assess perceived self-efficacy., To evaluate caregiver burden, the Zarit Burden Interview (ZBI) questionnaire will be completed., Expenditures related to in-hospital care will be extracted from hospital claims data. All other healthcare-related costs will be gathered through telephone interviews with patients, conducted each month after treatment initiation. During these calls, researchers will ask patients whether they have had any medical consultations, hospital admissions, AEs, changes in medication (daily morphine or MED), or incurred any additional healthcare costs., Safety, all (S)AEs will be documented throughout the duration of the study. HRQoL will be evaluated with the EORTC QLQ-C30 questionnaire.
Description
Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental, and social dimension., The survival rate in both groups, CMM and IDD, will be determined by recording the time from treatment initiation until death., Pain intensity will be measured with the VAS (ranging from 0 (no pain) to 100 (maximal pain)) in electronic format., Perceived stress will be assessed by using the 10-item Perceived Stress Scale (PSS; Cohen, Kamarch, & Mermelstein, 1983)., Patient anxiety will be provided through the State Trait Anxiety Inventory (STAI)., Using the Injustice Experience Questionnaire (IEQ), perceived injustice related to current health status will be assessed., The General Self-Efficacy (GSE) Scale is a 10-item self-report questionnaire used to assess perceived self-efficacy., To evaluate caregiver burden, the Zarit Burden Interview (ZBI) questionnaire will be completed., Expenditures related to in-hospital care will be extracted from hospital claims data. All other healthcare-related costs will be gathered through telephone interviews with patients, conducted each month after treatment initiation. During these calls, researchers will ask patients whether they have had any medical consultations, hospital admissions, AEs, changes in medication (daily morphine or MED), or incurred any additional healthcare costs., Safety, all (S)AEs will be documented throughout the duration of the study.
Who can participate
Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 72 participants
Interventions
MORPHINE HCl STEROP 10mg/1ml Oplossing voor injectie
Drug
MARCAINE 0,5%, oplossing voor injectie
Drug
Ropivacaïne Fresenius Kabi 5 mg/ml oplossing voor injectie
Drug
MORPHINE HCl STEROP 40mg/1ml Oplossing voor injectie
Drug
Locations 1
Belgium (1)
Technical details
Status
Recruiting
Phase
Phase 4
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
04.03.2026
Registry ID
2025-522381-68-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.